Clinical Trial Detail

NCT ID NCT03976362
Title A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung squamous cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Olaparib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.